

Clinical trials of exenatide 10g twice daily

TrialResults-center www.trialresultscenter.org

1 diabetes type 2

Trial	Treatments	Patients	Trials design and methods
exenatide 10g twice daily vs liraglutide 1.8mg			
LEAD 6 (Buse) exe vs lira , 2009 n=NA	-	-	

More details and results :

- insulin secretagogues peptides (incretins) for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q381>

References

LEAD 6 (Buse) exe vs lira, 2009:

Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47 [[19515413](#)] [10.1016/S0140-6736\(09\)60659-0](https://doi.org/10.1016/S0140-6736(09)60659-0)

Entry terms: nouveau, exenatide, exendin 4, exendin-4, Ex4 peptide, Byetta, AC 2993, AC 2993 LAR,